Scotland's Drug Deaths Crisis

Scotland's drug-related death statistics are compiled annually by National Records of Scotland through a standardised, internationally comparable methodology, giving the headline figures in this article a strong evidentiary basis. International comparisons (Scotland versus other UK nations and European countries) draw on cross-national drug mortality reporting, which involves some methodological variation between countries in how deaths are classified and recorded — a caveat public health researchers themselves note when making European comparisons, even though Scotland's relative position at or near the top of European rankings has been consistent across multiple years and data sources. This article covers the crisis strictly in terms of scale, demographics, and policy response. In line with public health and harm-reduction best practice, it provides no information about drug use methods, dosages, or means of self-harm, and treats substance use and addiction as a public health matter rather than a matter of individual blame.

Scale and scope

Scotland's drug-related death rate has, for close to a decade, been the highest recorded anywhere in Europe, a distinction confirmed repeatedly in National Records of Scotland's annual statistical releases and in cross-national comparative drug-mortality reporting. The scale is significant in both absolute and relative terms: Scotland's population is a little over 5.5 million, yet it has recorded over a thousand drug-related deaths in most recent years — a per-capita rate roughly two to three times that of England, Wales, and Northern Ireland, despite all four nations sharing broadly similar drug markets and UK-wide drug classification law.

The 2024 figures show encouraging movement in the right direction: 1,017 deaths, a 13% decrease from 2023 and the lowest annual total since 2017, following a long period of rising numbers that peaked at 1,339 deaths in 2020. Public health officials have cautioned against reading a single year's improvement as confirmation of a sustained downward trend, given the volatility the data has shown over previous years, including a major increase in the early 2020s linked in part to the pandemic's disruption of treatment services and social support networks.

The demographic pattern of the crisis is well documented and has shifted significantly over time. The average age at death has risen sharply, from 32 in 2000 to 45 in 2024, reflecting an ageing cohort of people who began long-term substance use in earlier decades and who now face compounding physical health vulnerabilities alongside substance dependence. Men account for more than twice the death rate of women. Most strikingly, National Records of Scotland data shows people living in Scotland's most deprived areas are around twelve times more likely to die a drug-related death than those in the least deprived areas — one of the starkest deprivation gradients recorded in any Scottish public health statistic, linking this crisis to the wider themes of deprivation and inequality covered elsewhere in this series.

Not a teenage crisis: what the schools surveys show

Because the crisis is so often discussed alongside youth drug use, it is worth being precise about what the evidence on young people actually shows. The Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS), carried out in 2004 by the University of Edinburgh's Child and Adolescent Health Research Unit for the Scottish Executive, questioned just over 7,000 pupils aged 13 and 15. Over a third (35%) of 15-year-olds and 13% of 13-year-olds said they had ever used drugs; 20% of 15-year-olds and 7% of 13-year-olds had done so in the previous month.

Almost all of that was cannabis. Nineteen per cent of 15-year-olds had used cannabis in the past month, and 14% had used cannabis and nothing else. Only 4% had combined cannabis with another drug, and just 1% had used another drug without cannabis. Friends of their own age were the most common source, and 63% of 15-year-olds said they had been offered a drug at some point, most often cannabis. Drug use in the past month was more common among pupils from low-affluence families, an early sign of the deprivation gradient that runs through the adult death figures.

The trend since was broadly downward, then partly reversed. Past-month drug use among 15-year-old boys fell from 26% in 1998 to 21% in 2004, and pupil drug use overall kept falling until 2013 before rising again. By 2018, 12% of 15-year-olds and 4% of 13-year-olds reported using drugs in the past month.

The point for this card is that the people dying are not, in the main, the teenagers these surveys describe. The deaths are concentrated in an older cohort, mostly aged 35–54, whose long-term opioid and polydrug dependence began in the 1980s and 1990s. The 15-year-olds of 2004 are now in their late thirties and entering that age band, but the survey shows their teenage drug use was overwhelmingly cannabis, not opioids. It cannot tell us which of them later developed problem drug use. Treating teenage experimentation and adult drug deaths as one story mixes up two different populations.

Causes

Public health researchers and the Scottish Government's own National Mission framework attribute the crisis to multiple, interacting factors rather than a single cause: a large, ageing cohort of long-term drug users whose health vulnerabilities compound over time; the increasing complexity and unpredictability ("toxicity") of the illicit drug supply, including the emergence of novel and highly potent substances; historic underinvestment in and fragmentation of drug treatment and harm-reduction services, particularly through the 2010s; and the same structural deprivation and health-inequality factors linked to Scotland's wider excess mortality patterns (see "The Glasgow Effect"). Researchers are broadly in agreement that no single factor explains the scale of Scotland's crisis relative to the rest of the UK, given that drug laws are set at a UK-wide level — pointing instead to a combination of Scotland-specific treatment-service history, demographic cohort effects, and deprivation patterns.

Policy response

Facing sustained criticism over the scale of deaths, the Scottish Government launched its "National Mission" on drug deaths in 2021, committing substantially increased funding to treatment capacity, harm reduction, and residential rehabilitation services, with annual monitoring reports tracking progress against this commitment. Naloxone — a medication that can reverse opioid overdose and has no potential for misuse — has been a central plank of the harm-reduction response, with national distribution programmes substantially expanded to make it available to people at risk and to their families, carers, and frontline service workers.

The most significant and internationally watched policy development has been the opening of The Thistle in Glasgow in January 2025 — the UK's first legally sanctioned safer drug consumption facility, where people can use their own previously obtained drugs under medical supervision in a controlled setting, with immediate access to overdose-reversal treatment and a route into wider health and social support services. The facility operates under a specific legal arrangement agreed with the Crown Office and Procurator Fiscal Service, since drug possession and use remain criminal matters under UK-wide law that the Scottish Parliament does not control. This arrangement itself reflects the deeper, ongoing constitutional and policy tension in this area: public health experts and harm-reduction advocates have long argued that a public-health-led approach, potentially including decriminalisation of possession for personal use, would do more to reduce deaths than criminal justice enforcement, while others — including some UK Government figures — have maintained that drug law and classification should remain a reserved, UK-wide matter and emphasised enforcement alongside treatment. This disagreement over the appropriate balance between public health and criminal justice approaches remains unresolved and is one of the most politically contested aspects of Scottish and UK drug policy.

Outlook

The 2024 fall in deaths has been cautiously welcomed by public health officials and the Scottish Government as the first substantial sign of improvement in several years, attributed tentatively to expanded treatment capacity, wider naloxone availability, and harm-reduction investment under the National Mission, though officials have been careful not to overstate confidence in the trend given the volatility seen in previous years' data. Scotland's rate remains the highest in Europe by a wide margin, and the Scottish Government, Public Health Scotland, and independent researchers continue to treat the crisis as an ongoing public health emergency requiring sustained, rather than one-off, policy attention.

• Scotland's drug-related death rate in recent years has been two to three times higher than the rest of the UK, despite drug classification law being set UK-wide.
• The average age of people dying a drug-related death in Scotland rose from 32 in 2000 to 45 in 2024, reflecting an ageing cohort of long-term users.
• People in Scotland's most deprived areas are around twelve times more likely to die a drug-related death than those in the least deprived areas.
• The Thistle, which opened in Glasgow in January 2025, was the first legally sanctioned drug consumption facility anywhere in the UK.
• Naloxone, the medication central to Scotland's harm-reduction strategy, has no potential for misuse and can be carried and administered by family members, carers, and frontline workers, not only medical professionals.
• In Scotland's 2004 national schools survey, just 1% of 15-year-olds had used a drug other than cannabis in the past month without also using cannabis. Teenage drug use was overwhelmingly a cannabis story.
• 2024 marked the first substantial annual fall in drug-related deaths since the figures peaked in 2020.
• Methadone, a medication used in opioid substitution treatment, was implicated in a substantial share of 2024's recorded drug deaths — a complexity that reflects the challenges of treating long-term opioid dependence rather than treatment itself being a primary driver of the crisis.
• Scotland's National Mission on drug deaths, launched in 2021, represented one of the largest dedicated funding commitments to drug treatment and harm reduction in the UK's history.

Scotland's drug deaths crisis is sometimes attributed in public discussion to a single cause — whether drug policy leniency, treatment-service failures, or the illicit drug supply alone — when researchers and government monitoring bodies consistently describe it as resulting from multiple interacting factors. The 2024 fall in deaths should not be read as evidence the crisis has been resolved; Scotland's rate remains the highest in Europe, and officials have been explicit that one year's improvement does not establish a confirmed long-term trend. The debate over decriminalisation versus continued criminal enforcement is genuinely unresolved and reflects a real difference in philosophy among experts and policymakers, not a question with an obvious or settled answer. It is also a mistake to treat teenage drug use and adult drug deaths as the same problem: school surveys such as SALSUS record mostly cannabis use by pupils present on the day, and they cannot show which young people later develop problem drug use. This article has deliberately avoided any detail about drug use methods, dosages, or means of self-harm, consistent with established harm-reduction communication guidance.